Bavarian Nordic A/S BAVA

COP: BAVA | ISIN: DK0015998017 5/05/2025

158,45 DKK (-0,69%)

(-0,69%) 5/05/2025

Grafiek Bavarian Nordic A/S

Grafiek Bavarian Nordic A/S

1 dag1d -0,69%
1 week1w 0,00%
1 maand1m 5,39%
3 maanden3m -6,96%
6 maanden6m -22,82%
1 jaar1j -4,38%
5 jaar5j -15,85%

Bavarian Nordic A/S in het nieuws

Toon enkel gratis nieuws

9 mei 2025 · Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such · Persbericht

9 mei 2025 · Bavarian Nordic Announces Interim Results for the First Three Months of 2025 · Persbericht

6 mei 2025 · Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines · Persbericht

2 mei 2025 · Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom · Persbericht

16 april 2025 · Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) · Persbericht

9 april 2025 · Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S · Persbericht

9 april 2025 · Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S · Persbericht

31 maart 2025 · Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine · Persbericht

12 maart 2025 · Bavarian Nordic A/S – Notice Convening Annual General Meeting · Persbericht

7 maart 2025 · Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older · Persbericht

Profiel Bavarian Nordic A/S

CEO: Paul Chaplin

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe